Please participate in our PEDSpace User Satisfaction Survey https://redcap.chop.edu/surveys/?s=79H8MN3YREN9HX37
A pediatrician checking in with a young patient.
About
Login

Explore PEDSpace Collections

Recent Submissions

  • PEDSnet Common Data Model - ETL Conventions
    Created:2026-07
    This document provides the ETL processing assumptions and conventions developed by the PEDSnet data partners that a data partner should use to ensure common ETL business rules. This record documents the changes for v6.3 or PEDSnet Database 2026-10.
  • PEDSnet Production Database
    Created:2026-10
    PEDSnet production database containing de-identified aggregate electronic healthcare information for ten contributing pediatric healthcare institutions. This database (2026-10) corresponds to Version 6.3 of the PEDSnet data model.

    Learn about how to access PEDSnet data for research here or, submit a collaboration request.
  • E-bike and E-scooted Injuries Managed in Pediatric Health Systems [Poster]
    Published:2026-11-02Journal:PEDSnet
    The use of e-bikes and e-scooters has risen rapidly, including among children. Yet, Multicenter data on pediatric injury trends, severity, and device differences remain limited. New ICD-10-CM external cause codes now make these injuries identifiable in EHRs. By capitalizing on these new coding practices, we used PEDSnet to examine trends and severity in e-bike and e-scooter use and benchmarked against non-motorized devices. Poster designed and presented by Sahal Master on October 14, 2026 at the Science, Population Health, Analytics, Research, Collaboration, Community (SPARCC) data summit.
  • Computational Biomedical Knowledge and the Language of Discovery: A Cross-Repository Metadata Evaluation [Poster]
    Journal:PEDSnet
    Patient cohorts in real world data analysis (RWD) are defined by computable, machine-executable definitions, or computable phenotypes. Access to well-described, reusable computable phenotypes, can reduce redundancy and improve reproducibility in RWD research. Therefore, systems to store and share phenotypes in accordance with FAIR principles is crucial. Despite broad consensus on the importance of sharing cohort-defining CBK, a key barrier to interoperability remains: the absence of a shared descriptive language. Phenotype and codeset repositories often operate in isolation and apply heterogeneous terminology and metadata, even for similar artifacts. A lack of standardized vocabularies limits discovery, comparison, and reuse across systems. Poster designed and presented by Annabel Pinkney on May 7, 2026 at the Medical Library Association Research Training Institute Virtual Poster Session.
  • Comparative Weight Change With Initiation and Adherence to Common Medications for Type 2 Diabetes
    Journal:Obesity
    **Objective:** This study aimed to estimate population-level effects on weight change of initiating/adhering to additional glucose-lowering medications in adults with type 2 diabetes prescribed metformin. **Methods:** We conducted a target trial using electronic health record data from 22,601 patients (age 20 to < 80 years) prescribed metformin to determine initiation/adherence to dipeptidyl peptidase IV (DPP4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), sodium-glucose cotransporter 2 (SGLT-2) inhibitors, long-acting insulin, or sulfonylureas. Inverse probability weighting of marginal structural models with standardization by baseline covariates was used to estimate population-level effects of initiating/adhering to different medications on average 24-month weight change. **Results:** At 24 months, a mean -5.15 kg (95% CI -10.6, -1.36) and -6.71 kg (95% CI -8.38, -4.34) weight loss would be observed for initiation/adherence to GLP-1RAs and SGLT-2s respectively. At 6 months, weight loss for DPP4s would be observed (-0.89 kg, 95% CI -1.41, -0.32) though not at 12 or 24 months. Glimepiride would be associated with weight gain at 6 and 12 months (0.88 kg, 95% CI 0.44, 1.22; 1.01 kg, 95% CI 0.32, 1.51) but not at 24 months. **Conclusions:** Initiation/adherence to GLP-1RAs and SGLT-2s over 24 months could result in average weight losses of 5.15 kg and 6.71 kg, respectively.